U.S. Markets closed

ANI Pharmaceuticals, Inc. (ANIP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.56+0.34 (+1.02%)
At close: 4:00PM EDT

33.56 0.00 (0.00%)
After hours: 4:00PM EDT

ANI Pharmaceuticals, Inc.

210 Main Street West
Baudette, MN 56623
United States
218 634 3500

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees369

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen P. CareySr. VP & CFO719.68kN/A1971
Mr. James G. MarkenSr. VP of Operations & Product Devel.608.59kN/A1963
Mr. Nikhil LalwaniPres, CEO & DirectorN/AN/A1978
Mr. Christopher K. MutzChief Commercial Officer & Head of Rare DiseasesN/AN/A1971
Mr. Ori GutwergSr. VP of GenericsN/AN/A1974
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Corporate Governance

ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.